

# Bayesian Safety Surveillance with Bias Correction

Fan Bu (UCLA)

on behalf of the OHDSI team collaborating with the FDA BEST Initiative



# Detecting risks of adverse events post vaccination

 $H_0$ : no increased risk (no signal) v.s.  $H_1$ : increased risk (signal)

- Key challenge: sequential data, with monthly/quarterly updates
- Standard practice: MaxSPRT (sequential test) + Historical Comparator (design)





#### MaxSPRT comes with burdens

• A <u>fixed</u> schedule must be pre-specified (to compute threshold)

Month	1	2	 12
Sample size (incremental)	100	150	 125

- What if ...
  - want to run longer? (e.g., 15 months, 2 years)
  - want to analyze at more frequent or coarse intervals?
  - have different sample sizes in real data?
- Not easy to correct for bias (systematic error)

Type 1 error inflation





#### We wish to develop a better alternative

- Bayesian sequential testing framework (details later)
- Comprehensive evaluation on real administrative databases:
  - Retrospective analysis of monthly data
  - Exposures: past vaccines (influenza, H1N1, HPV, Zoster etc.)
  - Outcomes: negative & positive control outcomes + one special outcome of interest (Guillain-Barré syndrome)
  - Evaluation of testing errors, time-to-detection, estimation accuracy, etc.
  - Benchmark against MaxSPRT (with historical rates design)

#### A Bayesian sequential analysis alternative

Testing via posterior probability  $P(H_1|data)$  using Bayesian posterior inference



- Update data evidence via posterior distribution
- **Retains rich information**
- Flat: weaker evidence
- Concentrated: stronger evidence

#### Posterior probability statements from dynamic updates

Testing via posterior probability  $P(H_1|data)$  using Bayesian posterior inference





## A Bayesian sequential analysis alternative

- Posterior probability  $P(H_1|data)$  using Bayesian posterior inference
- Joint model for bias correction using negative control analysis



# Bayesian bias correction helps control Type 1 error





#### If allow higher $\alpha$ , Bayesian can give higher power



Matching MaxSPRT Type 1 at 0.271: statistical power for different effect sizes.



## The tradeoff between $\alpha$ and power

- For initial screening, high-sensitivity but low-specificity might be desirable (don't want to miss a signal!)
- However, claiming (& believing)  $\alpha = 0.05$  but in fact  $\alpha >> 0.05$  is not best statistical practice
- MaxSPRT handles sequential multiplicity but not bias
- A Bayesian alternative can target bias in a coherent, principled manner
- Why not relax  $\alpha$  & use a better method?



#### Summary

- Bayesian framework presents a better alternative for safety surveillance
  - <u>Flexible</u>: no need for fixed schedule
  - <u>Less bias</u>: targets bias (from systematic error) & decreases Type 1 error
  - **Powerful**: has sufficient power, esp. if higher  $\alpha$  allowed
- Still work to be done:
  - (ongoing) Double threshold testing with futility early-stopping (saves time when confident about safety!)
  - (ongoing) Theoretical/empirical validation of error control with unbounded time horizon
  - Plug-and-play designs without likelihood?



#### Resources

- Team (@OHDSI):
  - Fan Bu
  - George Hripcsak
  - Kristin Kostka
  - David Madigan
  - Jody-Ann McLeggon

- Aki Nishimura
- Patrick Ryan
- Louisa Smith
- Marc Suchard
- Special acknowledgements to FDA CBER center for guidance and support!
- Links:
  - Study protocol: <u>https://suchard-group.github.io/Better/Protocol.html</u>
  - Study package: <u>https://suchard-group.github.io/Better/</u>
- Contact to participate: Marc Suchard (Teams) or <u>msuchard@ohdsi.org</u>